Mineralys Therapeutics, Inc. (MLYS) Stock Score, Valuation & Financial Research

Mineralys Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MLYS

Mineralys Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 21.95. These figures are a research snapshot, not a buy or sell recommendation.

What Mineralys Therapeutics, Inc. does

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Mineralys Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of proprietary medicines, specifically aldosterone synthase inhibitors, to treat hypertension and related comorbidities, with the goal of eventually commercializing these products upon regulatory approval.

Products and services

  • The company's primary product candidate is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor currently in clinical development for the treatment of hypertension and related conditions.

Brands and product families

  • lorundrostat — Proprietary, orally administered, highly selective aldosterone synthase inhibitor. Source

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various entities developing therapies for hypertension, chronic kidney disease, and obstructive sleep apnea, including those with larger resources and established commercial products. Source

Business strengths to evaluate

  • Clinical validation of lorundrostat through multiple successful trials Source
  • Strong cash position to support ongoing development activities Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single product candidate, lorundrostat Source
  • Regulatory risks associated with FDA approval processes Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MLYS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 21.95
Market capitalization:
1.94B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -349.58M
Free cash flow:
USD -142.43M
Cash:
USD 138.27M
Total debt:
USD 97.62M
EPS:
USD -4.24

What stands out

  • Free cash flow is USD -142.43M, negative for the stored period.
  • The balance sheet shows USD 138.27M of cash versus USD 97.62M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 40.65M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MLYS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MLYS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does MLYS's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for MLYS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MLYS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research MLYS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.